Greenwich LifeSciences (GLSI) Expected to Announce Earnings on Tuesday

Key Points

• Greenwich LifeSciences is expected to report quarterly results after the market close on April 21, with analysts forecasting EPS of ($0.32); the stock opened at $27.49 on the day, up about 6.6%.
• Analyst coverage is mixed—two Buy and one Sell—producing a consensus rating of Hold and a consensus target price of $47.50, while HC Wainwright raised its price objective to $50.
• Institutional investors (notably Vanguard, Geode and State Street) have recently increased positions—institutions own about 4.16%—and the company is a clinical-stage biotech focused on developing immune modulators for cancer and autoimmune diseases.

Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) is expected to release its results after the market closes on Tuesday, April 21st. Analysts expect Greenwich LifeSciences to post earnings of ($0.32) per share for the quarter.

Greenwich LifeSciences Stock Up 6.6%

GLSI stock opened at $27.49 on Tuesday. Greenwich LifeSciences has a fifty-two week low of $7.78 and a fifty-two week high of $34.10. The firm's 50-day simple moving average is $25.72 and its 200 day simple moving average is $18.38. The stock has a market cap of $380.74 million, a PE ratio of -18.83 and a beta of 1.53.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on GLSI. Wall Street Zen upgraded shares of Greenwich LifeSciences from a "sell" rating to a "hold" rating in a research report on Saturday, December 27th. Weiss Ratings restated a "sell (d-)" rating on shares of Greenwich LifeSciences in a research report on Monday, December 29th. Finally, HC Wainwright raised their price objective on shares of Greenwich LifeSciences from $39.00 to $50.00 and gave the company a "buy" rating in a research report on Tuesday, December 30th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $47.50.

Hedge Funds Weigh In On Greenwich LifeSciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in Greenwich LifeSciences by 4.9% during the third quarter. Vanguard Group Inc. now owns 282,181 shares of the company's stock valued at $2,808,000 after acquiring an additional 13,179 shares in the last quarter. Geode Capital Management LLC raised its position in Greenwich LifeSciences by 6.7% during the fourth quarter. Geode Capital Management LLC now owns 151,684 shares of the company's stock valued at $3,187,000 after acquiring an additional 9,568 shares in the last quarter. State Street Corp raised its position in Greenwich LifeSciences by 19.3% during the fourth quarter. State Street Corp now owns 97,777 shares of the company's stock valued at $2,054,000 after acquiring an additional 15,831 shares in the last quarter. Marshall Wace LLP bought a new position in Greenwich LifeSciences during the second quarter valued at approximately $509,000. Finally, Man Group plc bought a new position in Greenwich LifeSciences during the fourth quarter valued at approximately $590,000. Institutional investors own 4.16% of the company's stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc NASDAQ: GLSI is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company's product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.